Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges

: Cell and gene therapy, offering unprecedented solutions for complex diseases, have attracted significant attention in both the scientific and financial communities. This article explores the tumultuous financial journey of companies specializing in these advanced therapeutic modalities. The discussion illuminates the volatility of share prices, challenges in valuation, and complexities in fundraising while delving into the inherent risks of the cell and gene therapy development pathway. Through an examination of various strategies, the article underscores the importance of diverse investment sources, robust collaborations, risk-sharing models, and portfolio diversification in ensuring financial stability. As the field burgeons, understanding these financial dynamics is paramount for stakeholders aiming to harness the transformative potential of cell and gene therapies.

Authors

Institutions

Publication Details

Journal
Applied Drug Research Clinical Trials and Regulatory Affairs
Published
2024-09-03
DOI
https://doi.org/10.2174/0126673371318424240813063046
Citations
1
Primary Topic
Private Equity and Venture Capital
Type
article
Field-Weighted Citation Impact
0.95
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges

Alexander James Spicer, Pierre-Albert Colcomb, Joab Williamson
1 citations
Applied Drug Research Clinical Trials and Regulatory Affairs
Private Equity and Venture Capital
0.95
article

Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges

Alexander James Spicer, Pierre-Albert Colcomb, Joab Williamson
article en
1 citations

Abstract

: Cell and gene therapy, offering unprecedented solutions for complex diseases, have attracted significant attention in both the scientific and financial communities. This article explores the tumultuous financial journey of companies specializing in these advanced therapeutic modalities. The discussion illuminates the volatility of share prices, challenges in valuation, and complexities in fundraising while delving into the inherent risks of the cell and gene therapy development pathway. Through an examination of various strategies, the article underscores the importance of diverse investment sources, robust collaborations, risk-sharing models, and portfolio diversification in ensuring financial stability. As the field burgeons, understanding these financial dynamics is paramount for stakeholders aiming to harness the transformative potential of cell and gene therapies.

Applied Drug Research Clinical Trials and Regulatory AffairsVol. 10
Financial Research (Hungary) (HU), Faron Pharmaceutical (Finland) (FI), Amer Sports (France) (FR)
Openalex Percentile: Top 20%
Private Equity and Venture Capital
0.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.